June 28 Company Quick Takes: FDA approves Pfizer's biosimilar of Avastin; plus Aimmune, PeptiDream, Novartis and Just/Teva

Pfizer gets second FDA-approved biosimilar with Zirabev approval
FDA approved Zirabev bevacizumab-bvzr from Pfizer Inc. (NYSE:PFE) to treat metastatic colorectal cancer; unresectable, locally advanced, recurrent

Read the full 246 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE